Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds.

BACKGROUND Endoscopic screening of families predisposed to pancreatic cancer is increasingly used, but the cost-effectiveness of screening is unknown. METHODS A decision analysis was used to compare one-time screening for pancreatic dysplasia with EUS to no screening in a hypothetical cohort of 100 members of familial pancreatic cancer kindreds. Abnormal EUS findings are confirmed with ERCP and patients with abnormal findings are candidates for total pancreatectomy. Lifetime medical care costs and life expectancy were modeled, and the main analysis was conducted from the third-party payer perspective. The base-case analysis assumed a 20% prevalence of pancreatic dysplasia and 90% sensitivity of EUS and ERCP. RESULTS Endoscopic screening was cost-effective, with an incremental cost-effectiveness ratio of $16,885/life-year saved. Screening was more cost-effective as the probability of dysplasia increased and as the sensitivity of EUS and ERCP increased. Screening remained cost-effective if the prevalence of dysplasia was greater than 16% or if the sensitivity of EUS was greater than 84%. Procedure costs had a limited impact on cost-effectiveness. CONCLUSIONS Endoscopic screening of carefully selected members of familial pancreatic cancer kindreds appears to increase patient life expectancy in a cost-effective manner. Screening should be performed in centers that have experience with endoscopic screening for pancreatic dysplasia. The cost-effectiveness of repeated screening remains to be determined.

[1]  G. Bommer,et al.  Intraductal proliferation in the pancreas and its relationship to human and experimental carcinogenesis , 2004, Virchows Archiv A.

[2]  Leonid Kruglyak,et al.  A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. , 2002, American journal of human genetics.

[3]  D. Provenzale.  Cost-effectiveness of screening the average-risk population for colorectal cancer. , 2002, Gastrointestinal endoscopy clinics of North America.

[4]  T. Brentnall,et al.  Inherited Pancreatic Cancer: Surveillance and Treatment Strategies for Affected Families , 2001, Pancreatology.

[5]  C. Crosta,et al.  Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. , 2001 .

[6]  M. E. Ryan,et al.  Risk factors for post-ERCP pancreatitis: a prospective, multicenter study. , 1997, Gastrointestinal endoscopy.

[7]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[8]  M. Goggins,et al.  Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. , 2000, Gastroenterology.

[9]  R. Holman,et al.  Life-expectancy projection by modelling and computer simulation (UKPDS 46). , 2000, Diabetes research and clinical practice.

[10]  A. Lowy,et al.  Surgical management of hereditary pancreatic cancer. , 2000, The Medical clinics of North America.

[11]  S. Martin,et al.  PANCREATIC CANCER SURVEILLANCE IN A HIGH-RISK COHORT: Is It Worth the Cost? , 2000 .

[12]  T. Brentnall.  Cancer surveillance of patients from familial pancreatic cancer kindreds. , 2000, The Medical clinics of North America.

[13]  D. Farley,et al.  Long-term results after surgery for chronic pancreatitis , 2000, International journal of pancreatology : official journal of the International Association of Pancreatology.

[14]  Jeffrey E. Lee,et al.  Cost and Utilization Impact of a Clinical Pathway for Patients Undergoing Pancreaticoduodenectomy , 2000, Annals of Surgical Oncology.

[15]  M. Kimmey,et al.  Early Diagnosis and Treatment of Pancreatic Dysplasia in Patients with a Family History of Pancreatic Cancer , 1999, Annals of Internal Medicine.

[16]  J. Lightwood,et al.  Pancreatic cancer: Total costs and utilization of health services , 1999, Journal of surgical oncology.

[17]  A. Sahai,et al.  Bile duct stones and laparoscopic cholecystectomy: a decision analysis to assess the roles of intraoperative cholangiography, EUS, and ERCP. , 1999, Gastrointestinal endoscopy.

[18]  R. Hruban,et al.  Pathology of incipient pancreatic cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  M C Weinstein,et al.  Gains in life expectancy from medical interventions--standardizing data on outcomes. , 1998, The New England journal of medicine.

[20]  R H Hruban,et al.  Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. , 1998, The American journal of surgical pathology.

[21]  N. Ray,et al.  Economic Consequences of Diabetes Mellitus in the U.S. in 1997 , 1998, Diabetes Care.

[22]  C. Moskaluk,et al.  p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. , 1997, Cancer research.

[23]  R H Hruban,et al.  Familial pancreatic cancer: a review. , 1996, Seminars in oncology.

[24]  S. Goodman,et al.  Overexpression of p53 protein in adenocarcinoma of the pancreas. , 1994, American journal of clinical pathology.

[25]  J. Cameron,et al.  Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. , 1994, The American journal of pathology.

[26]  D. Eddy.  Screening for cervical cancer. , 1990, Annals of internal medicine.

[27]  J. Habbema,et al.  The cost‐effectiveness of breast cancer screening , 1989, International journal of cancer.

[28]  A. Cubilla,et al.  Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. , 1976, Cancer research.